Revvity Inc vs Americas Gold and Silver Corporation Common Shares no par value — how do they compare? Revvity Inc trades at $151.84 (market cap $17.30B), while Americas Gold and Silver Corporation Common Shares no par value trades at $3.91 (market cap $1.36B). The key difference: Revvity Inc is far larger — about 12.7× Americas Gold and Silver Corporation Common Shares no par value's market cap, and Revvity Inc pays a 0.18% dividend while Americas Gold and Silver Corporation Common Shares no par value pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 13 Days and Americas Gold and Silver Corporation Common Shares no par value for 0 Days on average.
| RVTY | USAS | |
|---|---|---|
Market Cap | $17.30B | $1.36B |
Volume | 1,387,588 | 3,177,621 |
Sector | Health | Basic Materials |
52-Week High | $157.36 | $10.03 |
52-Week Low | $82.26 | $3.59 |
Typical Hold Time | 13 Days | 0 Days |
Enterprise Value | $19.62B | $1.29B |
Dividend Yield | 0.18% | — |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.08, down 0.34% on the day but near its 52-week high of $158.28. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. The company maintains solid profitability with 54.98% gross margins and positive cash flow trends.
RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics (P/E 74.56) require careful consideration. Near-term catalysts include Q3 earnings on November 3, 2026, while risks involve China market pressures and margin compression. Analyst consensus leans bullish with 52% buy ratings and a $132.13 price target, suggesting potential downside from current levels despite positive momentum.
USAS trades at $4.02, down 4.29% on the day, reflecting ongoing volatility amid mixed operational performance. The company reported a net loss of $87.45M in 2025, though revenue is projected to grow to $182M in 2026 with a narrowing loss. Recent news highlights progress at its Galena and Cosalá mines, including high-grade silver discoveries and sustainability initiatives, signaling potential for future production growth.
The outlook is speculative, with high-risk turnaround potential driven by operational improvements and exposure to silver and critical minerals. Key risks include persistent negative profitability, high valuation multiples like EV/EBITDA of 455.68, and reliance on successful mine development. Analyst consensus is unanimously bullish, but investors must weigh execution risks against long-term growth prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →Americas Gold and Silver Corporation is a Canada-based mining company that explores for and produces silver, along with by-product gold, copper, lead, and zinc. Its operating assets include the Galena Complex in Idaho and the Cosalá Operations in Sinaloa, Mexico.
Read more on USAS →